about
Augmented osteogenic responses in human aortic valve cells exposed to oxLDL and TLR4 agonist: a mechanistic role of Notch1 and NF-κB interaction1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients.Tanshinone IIA Inhibits Growth of Keratinocytes through Cell Cycle Arrest and Apoptosis: Underlying Treatment Mechanism of Psoriasis.Cross-talk between the Toll-like receptor 4 and Notch1 pathways augments the inflammatory response in the interstitial cells of stenotic human aortic valves.Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2.Notch1 promotes the pro-osteogenic response of human aortic valve interstitial cells via modulation of ERK1/2 and nuclear factor-κB activation.Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia.High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.Characteristics of ATP-activated current in nodose ganglion neurons of rats.How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experienceComparative efficacy and safety of antithrombotic therapy for transcatheter aortic valve replacement: a systematic review and network meta-analysis
P50
Q33583872-CAE9AC85-04DB-4276-A74D-2DB4AAE93398Q33583872-D9E8AE8C-B11D-4D52-9D00-3C0BD76957F9Q35088508-4E017068-C28F-49FA-8F5D-EC33B47AC33FQ35607982-1124D346-52CD-47EE-A48C-BBCCAC97EDEFQ36422891-D604ACA1-50AC-4013-BA78-DEC73DD8E509Q36880524-407ABC9F-B7BC-4767-93C1-4059F6464CEFQ37185495-5722410E-E435-4BEA-9CF0-D76C6F484396Q39035187-016A4F18-BC51-4C91-9028-36E3A9A0B533Q44260275-04E67EA1-7C26-49EE-A077-CF143A93AB51Q45105047-894328BB-4E3F-4AD0-A8BB-6F8D2342EFCAQ46028540-82BEA18A-0514-4FD7-A0D7-252B5AB1FCEFQ53098336-B9E0D399-BE4D-468B-8ADA-6B7E85BA1021Q53142554-382BAAEF-5688-42B5-96DE-84354D07EBD6Q82263678-062BAA67-7244-4342-A6B0-8C1F0E954A22Q92292870-B4FD07D3-8485-4A7E-9509-48203FFCEF10
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Qing-Chun Zeng
@ast
Qing-Chun Zeng
@en
Qing-Chun Zeng
@es
Qing-Chun Zeng
@nl
type
label
Qing-Chun Zeng
@ast
Qing-Chun Zeng
@en
Qing-Chun Zeng
@es
Qing-Chun Zeng
@nl
prefLabel
Qing-Chun Zeng
@ast
Qing-Chun Zeng
@en
Qing-Chun Zeng
@es
Qing-Chun Zeng
@nl
P106
P31
P496
0000-0001-7665-8237